We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva…
Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company had sought…
Paul Ausick Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a trial in…
Paul Ausick US equity markets opened lower this morning, but after the first hour or so of trading, the three major indexes moved to positive territory where they remained for the rest of the…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning. AON Corporation (NYSE: AON) Cut to Neutral at Citigroup.…
Today is Facebook Day. It will be remembered that way as long as there are IPOs. The Facebook public offering has every aspect of what makes IPOs the focus of so much interest.…
Drug maker AstraZeneca PLC (NYSE: AZN) has issued a press release re-confirming the company’s December forecast following a load of bad data sent to analysts: During a routine consensus collection process, confidential…
Paul Ausick Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed earlier forecasts. Looking…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning. AstraZeneca PLC (NYSE: AZN) Cut to Underweight at JPMorgan. BlackRock,…
Pharmaceutical company AstraZeneca plc (NYSE: AZN) is looking for another big winner to replace its Nexium heartburn drug and its Seroquel schizophrenia treatment. Unfortunately two drugs the company had in trials both…
Paul Ausick Layoffs were part of the business news yesterday. Enough people lost jobs in a series of three “downsizings” to reminds those who believe unemployment continues to fall that the economy still struggles.…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie…
Equities started the day with a solid move up, but lost momentum after about half an hour. The downward move lasted into the late morning, at which time stocks started a fitful…
These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Aixtron SE (NASDAQ: AIXG) Raised to Equalweight at Morgan Stanley. Alcatel-Lucent SA (NYSE: ALU) Cut…
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and…
